Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma

Aberrant B-cell receptor (BCR) signaling is a key driver in lymphoid malignancies. Bruton tyrosine kinase (BTK) inhibitors that disrupt BCR signaling have received regulatory approvals in therapy of mantle cell lymphoma (MCL). However, responses are incomplete and patients who experience BTK inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Thieme, Elana, Liu, Tingting, Bruss, Nur, Roleder, Carly, Lam, Vi, Wang, Xiaoguang, Nechiporuk, Tamilla, Shouse, Geoffrey, Danilova, Olga V., Bottomly, Daniel, McWeeney, Shannon K., Tyner, Jeffrey W., Kurtz, Stephen E., Danilov, Alexey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927405/
https://www.ncbi.nlm.nih.gov/pubmed/35296646
http://dx.doi.org/10.1038/s41419-022-04684-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927405/
https://www.ncbi.nlm.nih.gov/pubmed/35296646
http://dx.doi.org/10.1038/s41419-022-04684-1

Ejemplares similares